Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Does anyone know if titan medical is trading on the German Stock Exchange?
I found this website that says it does???
Ticker QTN
www.bloomberg.com/research/stocks/people/board.asp?ticker=QTN:GR
If link doesn't work google, titan medical inc German stock exchange
Barker exercised his 34,632 options at .24 a share, not a bad ROI
Not trying to be a negative nancy like a see you next Tuesday, but why has the CFO sold over 30,000 shares in last year?? Does he know something we don't ???
Anyone with some insight please do share
Check it out for yourself
https://canadianinsider.com/node/7?menu_tickersearch=Titan+Medical+Inc.+%7C+TMD
As the bicker continues, we all should realize this is a forum for promotion of a stock that he or she chooses to invest in.
The antagonist might say boom gloom doom and management has trucked up the price per share for every holder like myself at 11k share at a avg pps at a buck sixty five
The protagonist continues to see through the gob shite of antagonism and see's this company as the apple of mis/surgery like the early apple that took xerox intellectual property and created the first graphic user interface and mouse to market.
Like all technologies what was so complex comes simplistic, for those of the latter reading this, remember intellectual property, for that is the true net worth of any major organization.
When an organization like Titan comes around with GAME CHANGING I.P, comes massive integration and acceptance, I am long and strong... Go Titan
Should we be buying on the TSX and not the OTC? Can someone advise what the difference is?
That's some serious viewership at 77 views.....
Maybe at 30 cents they will hit 78
911 shares traded today by market makers, pending news???
MARKET MAKER SIGNALS
Penny traders believe that Market Makers (MM) will "signal" moves in advance buy using small amounts of buys or sells as "signals". The "signals" are such a small amount of shares (worth no more than 5 or 10 dollars) that no trader would have paid a commission that costs more than the amount of shares bought. The "signals" are from one MM to another.
100 - I need shares.
200 - I need shares badly,but do not take the stock down.
300 - Take the price down so I can load shares
400 - Keep trading it sideways.
500 - Gap the stock. This gap can be either up or down, depending on the direction of the 500 signal.
911 - Pending News
I personally gotta thank lefty, cuin, and dak, for keeping my resolve during these tremendous buying opportunities.
I am a long, but like most OTC's this ticker is coming with left and right hooks and the unquestionable knockout punches......
I have taken the most unethical approach in stocks and have put my one egg of 20k of hard earned potatoes towards an industry that I believe in... Unfortunately because of Ebola and the economy my average price per share is around 2.... No excuses, excuses are for millionaires..
Whether we weather this storm or the storm swallows, I will remember the hands on deck and the journey we took...
Long and strong
El caribes please take a cruise to
The carribean. Its imperative you take your pc and cell phone with you.
Why is it imperative you ask? Cause after your wife pushes you in, first and foremost on the drop into the water you will realize every day is a blessing and you will turn your negative frown upside down.
More importantly to the board your posts will not be missed, and by the time you get out of the hospital titan will be soaring.
Shut the front door with your negative posts, we don't wanna hear your jaw.
My brother in law is an Olympus medical device rep and was at the community general hospital in Syracuse Ny recently. He told me a story how one of their Davinci SI's arm broke, and intuitive was gonna charge150k to fix the arm.
The arm broke literally during surgery, and had four procedures scheduled that day. Two of the four patients were under anaesthesia to make matters worse.
He literally watched a fifty year old doctor kick/curse this huge machine and move it to a wing in the hospital where it would take up empty space while they have to wait for the red tape to approve the fix. (Not to mention are losing $1000's per hour)
Bottom line is he confirmed what the docs were saying in dak's video. The Davinci is not cost effective for the hospital to continue with robotic procedures.
Henry ford brought cars to the masses in the early 1900's, Bausch and Lomb brought prescription glasses to the masses in the 1940's, Titan will bring robotic surgeries to the masses by next year.
Just a quick add to that, when I sat down with an Olympus Medical sales rep, he informed me that John Valvo, M.D. left his physicians office to commit a third of his time towards titan and their vision.
Sort of compliments the press release as these gentleman are for real, and it's almost go time
LTG, lets start over. Let me say I am sorry for getting emotional. Your consistent posting of tranny,plugging robincrookdotcom is something i am not too fond off. Robotic surgery is the future, no fees with trades are something we can both agree on. Do me a favor forgive me for not liking your constant spamming.
LTG cry me a river, your spamming robin crook dot com tranny posts are not for this bored, get lost like your money in a sheet stock. You are the weakest link, good bye
Hey LTG eat Sheet and shut the front door, do you dumb dic self a favor a check out the surgery advisory board on titans website... Eat sheet and cry u mother trucker, get off this board and ur spamming Robin Hood sheet
Thanks for the response CUIN2, and Geo, I guess my main concern as an investor is that we are less likely to sky rocket as I once thought.. If we double or triple with our shares outstanding at 100m plus that is a win in of itself... But a 10-20 plus share/price is an unrealistic goal at this time
Question to the board? ISRG trades at 470+ with only 35million shares outstanding, titxf trades at 2+ with 101million shares outstanding....
What does this mean for long investors?
Are we do for a I for 3, please explain this many shares and golf pro, honey and CUIN please chime in
Gotta luv when you google "robotic surgery companies" titan comes up number two to you know who! This has been like that in google results since my first investment at .96 back in December of '13 when a local surgeon in rochester ny told me about titan at a local credit union. Not for nothing but at least brooks did enhance credibility for this firm early on with seo on the world largest search engine
News? Am I missing something? I can't find the news.......
Met an Olympus Medical rep last night that is bullish on titan. He was telling me he bumps into intuitive reps in the surgical rooms often and told me that isrg reps are dreading 2016. He told me right now the major push for isrg is to lock in existing clients to 5-10 year service agreements. He made me aware that isrg is privy to titan and they fear this company!
New surgery advisory board, new patents, new write ups, seems as titan is like a tightly coiled spring ready to bounce high as the sky
Nautilus: Team’s tiny robot called medical science ‘breakthrough’
Experimental setup of the IREP, a robotic surgical tool created by engineers and surgeons at Vanderbilt and Columbia.
A miniscule robotic surgical tool created by engineers and surgeons at Vanderbilt University and Columbia University is singled out by Nautilus science magazine with four other remarkable developments as “unlikely breakthroughs” in medical science with potentially widespread applications.
The Nautilus article, released today, is part of a monthly package of articles on a single topic. Each Thursday Nautilus publishes a new chapter on a topic online. Issue 004’s topic is “The Unlikely.”
Under “Lilliputian Surgeons,” the article describes an image guided in-vivo surgical tool developed by Nabil Simaan at Vanderbilt and Peter Allen and Dennis Fowler at Columbia.
The Insertable Robotic Effector Platform (IREP) can enter the body through a single 15 millimeter incision.
The Insertable Robotic Effector Platform (IREP) can enter the body through a single 15 millimeter incision, unfold from its capsule and, following a surgeon’s instructions, move toward a particular organ to execute surgical tasks, such as clamping arteries and tying sutures, author Lina Zeldovich reports.
IREP has gone through several development stages. Zeldovich writes, “First, Columbia University computer scientist Peter Allen devised an insertable camera that tilted, panned, and followed the movements of surgical instruments from inside the abdomen, and projected its vision onto a computer screen.
Simaan
“To test it, surgeon Dennis Fowler performed a number of appendectomies, nephroscopies, and other operations on porcine models. Then, mechanical engineer Nabil Simaan at Vanderbilt University equipped IREP with two snake-like arms built from a series of vertebrae strung together with wires, which can bend and twist the arms in the required directions. Simaan also gave IREP wrists and grippers to manipulate objects.
“IREP was tested using the standard laparoscopic surgery exam setting, which all surgeons must pass to be board-certified. It passed the test, but has not yet been used on humans.
“Fowler says that IREP’s dexterity in maneuvering around tissues and organs can be better for patients than the surgeons’ standard laparoscopic graspers and dissectors. It can also reduce the size and number of incisions in the more invasive surgeries.”
IREP wrist gripper
Simaan’s current research interests include synthesis of novel robotic systems for surgery in confined spaces with applications to minimally invasive surgery of the throat, natural orifice surgery, cochlear implant surgery, dexterous bimanual microsurgery, and retinal micro-surgery.
“One of the cores of my research is developing algorithms that will enable intelligent surgical robots to help surgeons adapt surgical plans based on in-vivo information gathered during surgery,” says Simaan, who directs the Advanced Robotics and Mechanisms Applications (ARMA) Laboratory at Vanderbilt.
Prior to joining the engineering school at Vanderbilt in 2010, Simaan was an assistant professor of mechanical engineering at Columbia. In 2009 he received a NSF Career Award for young investigators to design new algorithms and robots for medical use.
Posted on Friday, August 2, 2013 in Alumni, Home Features, Mechanical Engineering, News, Research.
Tags: ARMA Lab, IREP, microsurgery, Nabil Simaan, surgical robots
50k Buy in L2, say what??
SeeUinThaBathroom4A#2 sell your position and stop wasting your breath
SeeUInTheBathroomForA#2 stop it all ready with the negative propaganda, we all get it... your infinite wisdom has maximized your price per share, and like Jesus you have walked on water and sold when the share price was at its peak.... We don't care .... shut the truck up about your crapulous and go in exodus like honeycomb
Development Milestone Link:
Management Discussion and Analysis
Published June 5, 2014
Please Scroll to Down Page 9
www.otcmarkets.com/financialReportViewer?symbol=TITXF&id=122163
Development Milestones:
The principal remaining milestones in the development of the Company’s robotic surgical system are set forth below:
Development Milestone
Estimated Cost – U.S.$
Anticipated Schedule for Milestone Completion
? Completion of the functional prototype -
Q3, 2013
Completed
? Alpha commercial prototype design complete
(design of prototype suitable for ongoing tissue testing)
- Q1, 2014
Completed
Completion of Clinical/Commercial Prototype
? Alpha commercial prototype built $2.7 million Q2, 2014
? Tissue testing complete
(testing performance of individual features and functionality)
$1.4 million Q2, 2014
? Tissue validation study complete
(formal statistically relevant study intended to demonstrate
safe and effective completion of surgical procedure)
$3.6 million Q4, 2014
? Product design completion and design verification
(building production equivalent product and confirming
product meets previously established specifications)
$3.6 million Q1, 2015
? Human clinical trials and regulatory submissions
(prepare for and conduct human trials, prepare for and submit
regulatory submissions)
$10.9 million Q2-Q4, 2015
? Outside U.S. approval process
(prepare and deliver submission packages to outside U.S.
regulatory agencies)
$1.8 million Q2, 2015
? Outside U.S. limited commercial launch
(technology transfer, manufacturing ramp up and launch)
$3.6 million Q2, 2015
? Process to shift to high volume manufacturing
(transfer of manufacturing processes and procedure, ramp up
of manufacturing)
$2.3 million Q3, 2015
? U.S. limited commercial product launch $1.8 million Q4, 2015
? Total at March 31, 2014 $31.7 million
I miss the jolly, jovial, intellectually intuitive long and strong CUIN2....
The new matter a fact death and doom, woah is me, CUIN2 is more like a CUNextTuesday...
Cheers to a boom to three on updates and milestones come 8/12/14
I agree TitanGold, I think CUIN is to busy plugging his other stocks and all of a sudden using his board credibility to sly other investors into his picks. Rather a shame and a nuisance, I would prefer no CUIN then the new fake pump and plug other stocks CUIN...
Posi - we also know your a paisan, reside in Jersey, probably Hudson County, my guess Jersey City or Hoboken, you have 10000 shares at average of .95
So yes why would you bs, and please do tell
It's not what you know in the world of business it's who you know....
All the departures CUIN noted could be perceived as negative departures...
but what if the spin was a positive play for titan
Why couldn't titan be implementing a sales strategy in the industry by ultimately planting the seeds of market share with reputable business men that will play key factors in implementing systems in there region of the country
I.E what if dr Valvo was influencing the follow organizations, university's, and business in Titans profound difference
Dr. John R. Valvo, MD : Street Credentials
University of Rochester School of Medicine and Dentistry. A member of the Society of Laparoendoscopic Surgeons, a Fellow of the American College of Surgeons, and a diplomat of the American Board of Urology, Dr. Valvo is also a clinical associate professor and Chief of Urology for Via Health in Rochester, and Executive Director of the Polissini Center for Robotic and Minimally Invasive Surgery at Rochester General Hospital
Timing is everything, we have ten months before human tissue testing, after results we get FDA approval and start selling ... Hate to pop any $20 / share bubbles but without a product to sell we sit anywhere from $2 - $4 in next 12 month window....
Around November December of next year is when it starts to get exciting .......
Making human repairs with precision
May 8th, 2014
Robotic Surgery is safer, less invasive
by Ron Johnson
“Tissue testing will continue for probably the next eight or nine months. The testing can vary from simply testing instruments by passing a needle through real tissue to an intended procedure, gall bladder surgery,” says Rayman. “We are testing with robotic surgeons in the field using several key opinion leaders.” The goal is to get their machines into operating rooms by 2015.
“We expect in approximately one year to begin initial human pilot studies, human clinical trials, probably outside the United States first,” says Randall. “Europe and Canada are also prime areas for testing the device. All testing will be approved through the regional regulatory bodies that exist right down to the particular hospital and the surgeon.”
You know who to ring the bell tomorrow on the New York stock exchange
http://online.wsj.com/article/PR-CO-20140707-908725.html
Poli Sci Geek as i agree with the deprogramming to programming aspect of sales
The reality that John Hargrove was named as Chief Executive of Office has everything to do with his background in sales.
Do your investment dollars a favor and read the portfolio of sales experience Hargrove has had in his role as a salesman.
" Following Johnson & Johnson, Mr. Hargrove joined Ohmeda Inc. as President, Corporate Account Management. While at Ohmeda, he successfully developed and implemented a multi-divisional corporate sales program, resulting in multi-year contracts with the majority of the largest Group Purchasing Organizations in the United States. Under Mr. Hargrove’s supervision, Ohmeda’s Corporate Account Division assisted buying groups, hospitals and integrated delivery networks in overall business and strategic planning and helped numerous customers who were under pressure to measure quality healthcare according to business as well as clinical and safety outcomes. Mr. Hargrove holds a Bachelor of Arts degree in Marketing from the University of Georgia and has completed executive management programs at Duke, Harvard and the University of Michigan".
The fact of the matter that the CEO is a silver tongue devil, has a tremendous sales rolodex and a track record to boot is why i have $$$$$ invested in a company with leadership.
Less guess more finesse
CEO of Titan is a Salesman
And a Bad Ass at That
Long And Straight Dicken Long Titan
Evolution of robotic surgery is in it's infancy .... Click below to learn how an octopus tentacle plays a role in the industry
http://www.newsweek.com/2014/06/20/researchers-craft-surgical-tools-inspired-octopus-tentacles-254473.html
GT70 you have an iq of a mentally challenged robot or you just have issues. Do us all a favor and shut the fluff up, and leave the intellectual dialogue to CUIN and the positive posters.
Thanks for the feedback C2 & IITF! Enjoy the evening, and lets GO TITAN!!!
Hi Board, follower for 6 months and over 8000 shares vested. I reside in Rochester Ny and truly excited to be apart of this ride! My question may be a bad one, but I wanted to ask about how a company can be on two stock exchanges. Is the TMD price directly related to the OTC price... How does that scenario play out for us investors on the OTC...